CNS Pharmaceuticals, Inc.
CNSPNASDAQHealthcare● Active
$4.89
$-0.11(-2.20%)
Market Cap$2809696
P/E Ratio—
52W High$12.48
52W Low$1.9
CNS Pharmaceuticals, Inc. (CNSP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CNSP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$7.30
Est. -$5.37 · -35.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
CNSP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.59B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.59B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$0.24 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$5.37 | -$7.30 | -35.9% | — | — | — |
| — Q1 FY2026 | Mar 31, 2026 | -$5.09 | -$5.09 | +0.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$6.63 | -$5.76 | +13.1% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$9.60 | -$6.42 | +33.1% | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.10 | -$150.06 | -149960.0% | — | — | — |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$3585.43 | -$4033.61 | -12.5% | — | — | — |
| — Q2 FY2024 | May 15, 2024 | — | -$12304.92 | — | — | — | — |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$7.30
EPS Est.
-$5.37
EPS Surpr.
-35.9%
Revenue
—
Q1 FY2026
Mar 31, 2026
EPS Actual
-$5.09
EPS Est.
-$5.09
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$5.76
EPS Est.
-$6.63
EPS Surpr.
+13.1%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$6.42
EPS Est.
-$9.60
EPS Surpr.
+33.1%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$150.06
EPS Est.
-$0.10
EPS Surpr.
-149960.0%
Revenue
—
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$4033.61
EPS Est.
-$3585.43
EPS Surpr.
-12.5%
Revenue
—
Q2 FY2024
May 15, 2024
EPS Actual
-$12304.92
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q3 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q2 FY2027 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Q1 FY2027 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q4 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q3 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -35.9% | $5.52 | $5.01 | -9.24% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +0.0% | $2.27 | $2.39 | +5.29% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +13.1% | $6.45 | $6.90 | +6.98% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +33.1% | $6.79 | $6.03 | -11.19% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -149960.0% | $74.76 | $71.40 | -4.49% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -12.5% | $88.20 | $83.16 | -5.71% |
| — Q2 FY2024 | May 15, 2024 | — | $6,231.00 | $5,988.00 | -3.90% |
| ▲ Q2 FY2024 | Apr 1, 2024 | +50.0% | No price data | $10,794.00 | — |
Q2 FY2026-9.24%
Report Date
May 14, 2026
EPS Beat/Miss
-35.9%
Price Before
$5.52
Price After
$5.01
Q1 FY2026+5.29%
Report Date
Mar 31, 2026
EPS Beat/Miss
+0.0%
Price Before
$2.27
Price After
$2.39
Q4 FY2025+6.98%
Report Date
Nov 14, 2025
EPS Beat/Miss
+13.1%
Price Before
$6.45
Price After
$6.90
Q3 FY2025-11.19%
Report Date
Aug 14, 2025
EPS Beat/Miss
+33.1%
Price Before
$6.79
Price After
$6.03
Q4 FY2024-4.49%
Report Date
Nov 14, 2024
EPS Beat/Miss
-149960.0%
Price Before
$74.76
Price After
$71.40
Q3 FY2024-5.71%
Report Date
Aug 14, 2024
EPS Beat/Miss
-12.5%
Price Before
$88.20
Price After
$83.16
Q2 FY2024-3.90%
Report Date
May 15, 2024
EPS Beat/Miss
—
Price Before
$6,231.00
Price After
$5,988.00
Q2 FY2024—
Report Date
Apr 1, 2024
EPS Beat/Miss
+50.0%
Price Before
—
Price After
$10,794.00
Avg Beat Reaction+0.36%
Avg Miss Reaction-6.48%
Beat Rate4 / 8 quarters
Largest Move-11.19% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CNSP ends December
CNS Pharmaceuticals, Inc. (CNSP) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-7.30 — missing the analyst consensus of $-5.37 by -35.9%. The next CNSP earnings date is expected around September 1, 2026.
Each quarter, investors track CNSP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CNSP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CNSP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CNSP earnings · 5 questionsCNS Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CNSP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CNSP historically reports after market close (AMC).
CNSP earnings datewhen is CNSP earningsCNSP next earnings datewhen does CNSP report earningsCNSP earnings calendar
▸ Source: FMP · CNS Pharmaceuticals, Inc. SEC filings · US GAAP · CNS Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026